abstract |
A compound of the formula (I) for treating a CCR2-mediated condition or disease or a CCR9-mediated condition or disease, where the disease or condition is selected from the group consisting of atherosclerosis, restenosis, multiple sclerosis, inflammatory bowel disease, renal fibrosis, rheumatoid arthritis, obesity, diabetes, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, idiopathic pneumonia syndrome, pulmonary fibrosis, transplantation rejection, graft- versus- host disease, cancer, and neuropathic pain wherein Ar is selected from the group consisting of substituted or unsubsituted Cβ-io aryl and substituted or unsubstituted 5- to 10- membered heteroaryl; Y1 to Y4 are selected from the group consisting of -CR3a- to -CR3d-, -N-, and -N+(O)-, wherein at least one of Y1, Y2, Y3, or Y4 is -N-. |